Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Sponsored by

Logo 22.07.22.png
Patented Patent Copyright Law Business technology concept.

Anne Marie Clark, senior patent searcher at CAS, looks at ways to protect and commercialise the promise of RNAi

The value and complexity of the patent landscape around RNA interference (RNAi) is increasing, creating special challenges for patent searches to protect IP and maximise its value.

RNAi is claimed in a variety of ways within patents. Standard terminology is not always used, and chemical modifications can be described a variety of ways. These inconsistencies mean that there is no single search strategy that can be used to efficiently and comprehensively retrieve this information from different data sources.

Read an in-depth discussion of relevant challenges and search techniques for RNAi in this resource from CAS

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

Monetisation is standing at the forefront of patent development, and one firm says AI is increasingly being deployed
Data centres are being built across the US, prompting patent disputes, but Texas’s thriving tech industry and patent-ready courts make the state particularly ‘ripe’ for litigation
Carpmaels & Ransford is set to bolster its UK attorney team with the appointment of Simmons & Simmons’s head of IP in the UK
Updates on Nokia’s licensing strides and a surge in patent activity around battery recycling in Australia were also among the top talking points
To mark International Day Against Child Labour, Matteo Amerio at Corsearch says the people inside businesses who can identify counterfeiting risks must be given the tools and authority to act
With genuine equity at IP firms becoming rarer, securing partnership is harder than ever, but increased transparency is also making climbing the ladder more predictable
Yossi Sivan explains how Israeli judgment is a pro-brand owner departure from the norm and why it sends a strong message that corporate structures are not always a shield
Halim Shehadeh, group CEO of IP firm CWB, says that in the rush to discuss what AI can do, IP firms are overlooking the more important question of whether they are ready
Caitlin Heard, who formally joined the firm from CMS last month, says she is excited by the ‘energy’ of the London office
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
Gift this article